Over the last 2 decades, there has been increasing widespread use of second-generation antipsychotic (SGA) medications in nonpsychotic pediatric populations in the United States and Europe. As the ubiquity of SGA drugs in treatment plans for these children and adolescents grows, so does the controversy surrounding them.